Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$53.83 USD
-0.03 (-0.06%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $53.80 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Protagonist Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
PTGX 53.83 -0.03(-0.06%)
Will PTGX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PTGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTGX
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Zeta (ZETA) Surges 12.6%: Is This an Indication of Further Gains?
PTGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Other News for PTGX
Deep Track Capital, LP Increases Stake in Tarsus Pharmaceuticals Inc
Insider Sell: PATEL DINESH V PH D Sells Shares of Protagonist Therapeutics Inc (PTGX)
Protagonist Therapeutics Inc (PTGX) Submits NDA for Icotrokinra to FDA | PTGX stock news
Protagonist Therapeutics, Johnson & Johnson submit icotrokinra NDA to FDA
Protagonist announces NDA submission by Johnson & Johnson for icotrokinra